Relmada Therapeutics (RLMD) Stock Forecast, Price Target & Predictions
RLMD Stock Forecast
Relmada Therapeutics stock forecast is as follows: an average price target of $5.67 (represents a 66.76% upside from RLMD’s last price of $3.40) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
RLMD Price Target
RLMD Analyst Ratings
Relmada Therapeutics Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Jun 05, 2024 | Andrea Tan | Goldman Sachs | $2.00 | $2.95 | -32.20% | -41.18% |
Oct 13, 2022 | Andrew Tsai | Jefferies | $8.00 | $6.47 | 23.55% | 135.29% |
Oct 13, 2022 | Jay Olson | Oppenheimer | $7.00 | $6.75 | 3.73% | 105.88% |
Relmada Therapeutics Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | - | - | 1 |
Avg Price Target | - | - | $2.00 |
Last Closing Price | $3.40 | $3.40 | $3.40 |
Upside/Downside | -100.00% | -100.00% | -41.18% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Sep 16, 2024 | Jefferies | - | Buy | Upgrade |
Jun 05, 2024 | Goldman Sachs | - | Sell | Downgrade |
Oct 13, 2022 | Oppenheimer | - | Perform | Downgrade |
Relmada Therapeutics Financial Forecast
Relmada Therapeutics Revenue Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - |
Avg Forecast | - | - | - | - | - | - | - |
High Forecast | - | - | - | - | - | - | - |
Low Forecast | - | - | - | - | - | - | - |
# Analysts | - | - | - | - | - | - | - |
Surprise % | - | - | - | - | - | - | - |
Relmada Therapeutics EBITDA Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - |
Avg Forecast | - | - | - | - | - | - | - |
High Forecast | - | - | - | - | - | - | - |
Low Forecast | - | - | - | - | - | - | - |
Surprise % | - | - | - | - | - | - | - |
Relmada Therapeutics Net Income Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - |
Net Income | - | - | - | - | - | - | - |
Avg Forecast | $-30.78M | $-26.86M | $-22.63M | $-19.01M | $-18.86M | $-20.37M | $-24.97M |
High Forecast | $-30.78M | $-26.86M | $-22.63M | $-19.01M | $-18.86M | $-20.05M | $-24.97M |
Low Forecast | $-30.78M | $-26.86M | $-22.63M | $-19.01M | $-18.86M | $-20.68M | $-24.97M |
Surprise % | - | - | - | - | - | - | - |
Relmada Therapeutics SG&A Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - |
SG&A | - | - | - | - | - | - | - |
Avg Forecast | - | - | - | - | - | - | - |
High Forecast | - | - | - | - | - | - | - |
Low Forecast | - | - | - | - | - | - | - |
Surprise % | - | - | - | - | - | - | - |
Relmada Therapeutics EPS Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - |
EPS | - | - | - | - | - | - | - |
Avg Forecast | $-1.02 | $-0.89 | $-0.75 | $-0.63 | $-0.63 | $-0.68 | $-0.83 |
High Forecast | $-1.02 | $-0.89 | $-0.75 | $-0.63 | $-0.63 | $-0.66 | $-0.83 |
Low Forecast | $-1.02 | $-0.89 | $-0.75 | $-0.63 | $-0.63 | $-0.69 | $-0.83 |
Surprise % | - | - | - | - | - | - | - |
Relmada Therapeutics Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
RAPT | RAPT Therapeutics | $2.72 | $42.20 | 1451.47% | Hold |
PMVP | PMV Pharmaceuticals | $1.66 | $24.75 | 1390.96% | Buy |
IPSC | Century Therapeutics | $1.39 | $20.00 | 1338.85% | Buy |
STTK | Shattuck Labs | $1.23 | $12.00 | 875.61% | Hold |
NUVB | Nuvation Bio | $2.54 | $6.75 | 165.75% | Buy |
ELYM | Eliem Therapeutics | $5.11 | $13.00 | 154.40% | Buy |
BCYC | Bicycle Therapeutics | $23.64 | $54.40 | 130.12% | Buy |
NAMS | NewAmsterdam Pharma Company | $21.78 | $36.50 | 67.58% | Buy |
RLMD | Relmada Therapeutics | $3.40 | $5.67 | 66.76% | Buy |
CYTK | Cytokinetics | $55.50 | $83.23 | 49.96% | Buy |
DYN | Dyne Therapeutics | $29.81 | $43.88 | 47.20% | Buy |
DICE | DICE Therapeutics | $47.55 | $60.00 | 26.18% | Buy |
GRPH | LENZ Therapeutics | $3.18 | $4.00 | 25.79% | Hold |
EWTX | Edgewise Therapeutics | $36.62 | $45.00 | 22.88% | Buy |
THRD | Third Harmonic Bio | $13.27 | $16.15 | 21.70% | Buy |
RVMD | Revolution Medicines, Inc. Warrant | $59.42 | $59.00 | -0.71% | Buy |
KRTX | Karuna Therapeutics | $329.83 | $257.50 | -21.93% | Buy |
FUSN | Fusion Pharmaceuticals | $21.55 | $15.25 | -29.23% | Hold |
CYT | Cyteir Therapeutics | $3.02 | $2.00 | -33.77% | Sell |
RLMD Forecast FAQ
Is Relmada Therapeutics a good buy?
Yes, according to 2 Wall Street analysts, Relmada Therapeutics (RLMD) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 50.00% of RLMD's total ratings.
What is RLMD's price target?
Relmada Therapeutics (RLMD) average price target is $5.67 with a range of $2 to $8, implying a 66.76% from its last price of $3.4. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Relmada Therapeutics stock go up soon?
According to Wall Street analysts' prediction for RLMD stock, the company can go up by 66.76% (from the last price of $3.4 to the average price target of $5.67), up by 135.29% based on the highest stock price target, and down by -41.18% based on the lowest stock price target.
Can Relmada Therapeutics stock reach $5?
RLMD's average twelve months analyst stock price target of $5.67 supports the claim that Relmada Therapeutics can reach $5 in the near future.
What are Relmada Therapeutics's analysts' financial forecasts?
Relmada Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-64.196M (high $-63.882M, low $-64.509M), average SG&A $0 (high $0, low $0), and average EPS is $-2.127 (high $-2.117, low $-2.138). RLMD's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-99.273M (high $-99.273M, low $-99.273M), average SG&A $0 (high $0, low $0), and average EPS is $-3.29 (high $-3.29, low $-3.29).